Cost Effectiveness of Cryptococcal Antigen Screening as a Strategy to Prevent HIV-Associated Cryptococcal Meningitis in South Africa

被引:95
作者
Jarvis, Joseph N. [1 ,2 ,3 ]
Harrison, Thomas S. [3 ]
Lawn, Stephen D. [1 ,2 ]
Meintjes, Graeme [4 ,5 ,6 ]
Wood, Robin [2 ,4 ]
Cleary, Susan [7 ]
机构
[1] London Sch Hyg & Trop Med, Fac Infect & Trop Dis, Dept Clin Res, London WC1, England
[2] Univ Cape Town, Inst Infect Dis & Mol Med, Desmond Tutu HIV Ctr, ZA-7925 Cape Town, South Africa
[3] St Georges Univ London, Res Ctr Infect & Immun, Div Clin Sci, London, England
[4] Univ Cape Town, Dept Med, ZA-7925 Cape Town, South Africa
[5] Univ Cape Town, Inst Infect Dis & Mol Med, Clin Infect Dis Res Initiat, ZA-7925 Cape Town, South Africa
[6] Univ London Imperial Coll Sci Technol & Med, Dept Med, London, England
[7] Univ Cape Town, Hlth Econ Unit, ZA-7925 Cape Town, South Africa
来源
PLOS ONE | 2013年 / 8卷 / 07期
基金
英国惠康基金;
关键词
IMMUNODEFICIENCY-VIRUS-INFECTION; SYSTEMIC FUNGAL-INFECTIONS; PRIMARY PROPHYLAXIS; ANTIRETROVIRAL THERAPY; DOUBLE-BLIND; ITRACONAZOLE PROPHYLAXIS; OPPORTUNISTIC INFECTIONS; FLUCONAZOLE PROPHYLAXIS; ACTIVE SURVEILLANCE; CONTROLLED TRIAL;
D O I
10.1371/journal.pone.0069288
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Objectives: Cryptococcal meningitis (CM)-related mortality may be prevented by screening patients for sub-clinical cryptococcal antigenaemia (CRAG) at antiretroviral-therapy (ART) initiation and pre-emptively treating those testing positive. Prior to programmatic implementation in South Africa we performed a cost-effectiveness analysis of alternative preventive strategies for CM. Design: Cost-effectiveness analysis. Methods: Using South African data we modelled the cost-effectiveness of four strategies for patients with CD4 cell-counts <100 cells/mu l starting ART 1) no screening or prophylaxis (standard of care), 2) universal primary fluconazole prophylaxis, 3) CRAG screening with fluconazole treatment if antigen-positive, 4) CRAG screening with lumbar puncture if antigen-positive and either amphotericin-B for those with CNS disease or fluconazole for those without. Analysis was limited to the first year of ART. Results: The least costly strategy was CRAG screening followed by high-dose fluconazole treatment of all CRAG-positive individuals. This strategy dominated the standard of care at CRAG prevalence >= 0.6%. Although CRAG screening followed by lumbar puncture in all antigen-positive individuals was the most effective strategy clinically, the incremental benefit of LPs and amphotericin therapy for those with CNS disease was small and additional costs were large (US$158 versus US$51per person year; incremental cost effectiveness ratio(ICER) US$889,267 per life year gained). Both CRAG screening strategies are less costly and more clinically effective than current practice. Primary prophylaxis is more effective than current practice, but relatively cost-ineffective (ICER US$20,495). Conclusions: CRAG screening would be a cost-effective strategy to prevent CM-related mortality among patients initiating ART in South Africa. These findings provide further justification for programmatic implementation of CRAG screening.
引用
收藏
页数:10
相关论文
共 53 条
[1]  
Apisarnthanarak A, 2008, JAIDS-J ACQ IMM DEF, V47, P644, DOI 10.1097/QAI.0b013e31815bad0c
[2]   Primary and opportunistic pathogens associated with meningitis in adults in Bangui, Central African Republic, in relation to human immunodeficiency virus serostatus [J].
Bekondi, Claudine ;
Bernede, Claire ;
Passone, Noella ;
Minssart, Pierre ;
Kamalo, Come ;
Mbolidi, Didier ;
Germani, Yves .
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2006, 10 (05) :387-395
[3]   The hidden danger of primary fluconazole prophylaxis for patients with AIDS [J].
Berg, J ;
Clancy, CJ ;
Nguyen, MH .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :186-187
[4]   High-dose amphotericin B with flucytosine for the treatment of cryptococcal meningitis in HIV-infected patients: A randomized trial [J].
Bicanic, Tihana ;
Wood, Robin ;
Meintjes, Graeme ;
Rebe, Kevin ;
Brouwer, Annemarie ;
Loyse, Angela ;
Bekker, Linda-Gail ;
Jaffar, Shabbar ;
Harrison, Thomas .
CLINICAL INFECTIOUS DISEASES, 2008, 47 (01) :123-130
[5]   Fungal burden, early fungicidal activity, and outcome in cryptococcal meningitis in antiretroviral-naive or antiretroviral-experienced patients treated with amphotericin B or fluconazole [J].
Bicanic, Tihana ;
Meintjes, Graeme ;
Wood, Robin ;
Hayes, Madeleine ;
Rebe, Kevin ;
Bekker, Linda-Gail ;
Harrison, Thomas .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (01) :76-80
[6]   UNCERTAINTY IN THE ECONOMIC-EVALUATION OF HEALTH-CARE TECHNOLOGIES - THE ROLE OF SENSITIVITY ANALYSIS [J].
BRIGGS, A ;
SCULPHER, M ;
BUXTON, M .
HEALTH ECONOMICS, 1994, 3 (02) :95-104
[7]   An introduction to Markov modelling for economic evaluation [J].
Briggs, A ;
Sculpher, M .
PHARMACOECONOMICS, 1998, 13 (04) :397-409
[8]   Antifungal interventions for the primary prevention of cryptococcal disease in adults with HIV. [J].
Chang, LW ;
Phipps, WT ;
Kennedy, GE ;
Rutherford, GW .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2005, (03)
[9]   A controlled trial of itraconazole as primary prophylaxis for systemic fungal infections in patients with advanced human immunodeficiency virus infection in Thailand [J].
Chariyalertsak, S ;
Supparatpinyo, K ;
Sirisanthana, T ;
Nelson, KE .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (02) :277-284
[10]   A multicentre, randomized, double-blind, placebo-controlled trial of primary cryptococcal meningitis prophylaxis in HIV-infected patients with severe immune deficiency [J].
Chetchotisakd, P ;
Sungkanuparph, S ;
Thinkhamrop, B ;
Mootsikapun, P ;
Boonyaprawit, P .
HIV MEDICINE, 2004, 5 (03) :140-143